Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6291623 | 0.85 | — | — | |
| SCHEMBL14559750 | 0.80 | ALDH1A1 (0.33) | ALDH1A1ALOX15 | |
| SCHEMBL6294462 | 0.80 | — | — | |
| SCHEMBL27957266 | 0.77 | ALDH1A1 (0.31) | ALDH1A1ALOX15 | |
| SCHEMBL11072482 | 0.77 | ALDH1A1 (0.31) | ALDH1A1ALOX15 | |
| SCHEMBL11073034 | 0.77 | ALDH1A1 (0.31) | ALDH1A1ALOX15 | |
| SCHEMBL11072025 | 0.75 | ALDH1A1 (0.30) | ALDH1A1ALOX15 | |
| SCHEMBL983841 | 0.74 | ALDH1A1 (0.36) | ALDH1A1ALOX15 | |
| SCHEMBL1050477 | 0.73 | ALDH1A1 (0.32) | ALDH1A1ALOX15 | |
| SCHEMBL8143210 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3141538-B1 | IMPROVED PROCESS STABILITY OF NBDE USING SUBSTITUTED PHENOL STABILIZERS | VERSUM MAT US LLC (US) | 2019-10-30 | — | — | EP | disclosed |
| EP-2318477-B1 | ADDITIVES TO PREVENT DEGRADATION OF CYCLIC ALKENE DERIVATIVES | FUJIFILM ELECTRONIC MAT USA INC (US) | 2019-06-05 | — | — | EP | disclosed |
| EP-3141538-A1 | IMPROVED PROCESS STABILITY OF NBDE USING SUBSTITUTED PHENOL STABILIZERS | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2017-03-15 | — | — | EP | disclosed |
| EP-2141141-B1 | Improved Process Stability of NBDE Using Substituted Phenol Stabilizers | AIR PROD & CHEM (US) | 2016-09-28 | — | — | EP | disclosed |
| EP-1931613-B1 | ADDITIVES TO PREVENT DEGRADATION OF CYCLIC ALKENE DERIVATIVES | FUJIFILM ELECTRONIC MATERIALS (US) | 2015-11-11 | — | — | EP | disclosed |
| CN-102089405-B | Additives to prevent degradation of cyclic alkene derivatives | FUJIFILM ELECTRONIC MATERIALS | 2013-10-16 | — | — | CN | disclosed |
| EP-1931746-B1 | ADDITIVES TO PREVENT DEGRADATION OF CYCLIC ALKENE DERIVATIVES | FUJIFILM ELECTRONIC MATERIALS (US) | 2013-09-04 | — | — | EP | disclosed |
| US-8252704-B2 | Additives to prevent degradation of cyclic alkene derivatives | FUJIFILM ELECTRONIC MATERIALS U.S.A., INC. (US) | 2012-08-28 | — | — | US | disclosed |
| CN-101591772-B | Process stability of nbde using substituted phenol stabilizers | AIR PROD & CHEM | 2012-07-04 | — | — | CN | disclosed |
| US-8173213-B2 | Process stability of NBDE using substituted phenol stabilizers | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| CN-1451009-A | Glucocortiocoid-selective antinflammatory agents | ABBOTT LAB (US) | 2003-10-22 | — | — | CN | disclosed |
| CN-1119348-C | glucocorticoid derivatives, compositions and uses thereof | ABBOTT INC (US) | 2003-08-27 | — | — | CN | disclosed |
| US-20030073703-A1 | Glucocortiocoid-selective antinflammatory agents | ABBOTT LABORATORIES AND LIGAND PHARMACEUTICALS INCORPORATED | 2003-04-17 | — | — | US | disclosed |
| EP-1299392-A2 | GLUCOCORTIOCOID-SELECTIVE ANTIINFLAMMATORY AGENTS | Abbott Laboratories (US) | 2003-04-09 | — | — | EP | disclosed |
| US-6506766-B1 | A pharmaceutical composition for use in treating inflammation, immune, autoimmune, and inflammatory diseases in a mammal by selectively modulating the activation, repression, agonism, and antagonism effects of the mammal's glucocorticoid | ABBOTT LABORATORIES | 2003-01-14 | — | — | US | disclosed |
| EP-1053239-B1 | GLUCOCORTICOID-SELECTIVE ANTI-INFLAMMATORY AGENTS | ABBOTT LAB (US) | 2003-01-08 | — | — | EP | disclosed |
| WO-2002002565-A2 | GLUCOCORTIOCOID-SELECTIVE ANTIINFLAMMATORY AGENTS | ABBOTT LABORATORIES (US) | 2002-01-10 | — | — | WO | disclosed |
| CN-1296486-A | Glucocorticoid-selective anti-inflammatory agents | ABBOTT LAB (US) | 2001-05-23 | — | — | CN | disclosed |
| US-4870062-A | REDUCED NEPHROTOXICITY | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 1989-09-26 | — | — | US | disclosed |
| EP-0288002-A2 | Organo-platinum complex and use thereof | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 1988-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073703-A1 | Glucocortiocoid-selective antinflammatory agents | NR3C1, GPR119, MC2R | ALDH1A1 3187/4885ALOX15 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.